Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential ...

Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug ...

Drugmakers Mallinckrodt and Endo have today completed their near $7 billion merger deal, which was first announced in March.

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - Pivotal Phase 3 LUCIDITY trial of ...

Ategenos, a pharmatech company, today announced that co-founder and CEO Don DeGolyer is leading the company as it prepares to ...

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 Provided by GlobeNewswire Jul 12, 2025, 3:00:00 PM ...

BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective ...

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 Rhythm Pharmaceuticals, Inc. - GlobeNewswire - Sat Jul 12, 5:00PM CDT ...

BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 ...

Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 July 13, 2025 — 05:50 pm EDT Written by None for Quiver Quantitative -> ...